Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Prevalence of Candida bloodstream isolates from patients in two hospitals in Vietnam.

Bac ND, Anh LT, Quang LB, Luc NK, Nga TTT, Nagi M, Yoshitsugu M, Ha HTT, Anh DD, Quyet D, Anh DN.

Iran J Microbiol. 2019 Apr;11(2):108-113.

2.
3.

Histoplasmosis among HIV-infected patients in Japan: A case report and literature review.

Hatakeyama S, Okamoto K, Ogura K, Sugita C, Nagi M.

Jpn J Infect Dis. 2019 Apr 26. doi: 10.7883/yoken.JJID.2018.354. [Epub ahead of print]

4.

Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Nakamura S, Ikeda-Dantsuji Y, Jin L, Higashi Y, Abe M, Inukai T, Nagi M, Urai M, Miyazaki Y.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e02364-18. doi: 10.1128/AAC.02364-18. Print 2019 Jun.

PMID:
30936099
5.

Atypical Palmaris Profundus with Median Nerve Perforation Presenting Ultrasonically as an Intraneural Mass.

Deglmann CJ, Nagi M.

Plast Reconstr Surg Glob Open. 2018 Nov 7;6(11):e1995. doi: 10.1097/GOX.0000000000001995. eCollection 2018 Nov.

6.

Can acetaminophen/dimethyl sulfoxide formulation prevent accidental and intentional acetaminophen hepatotoxicity?

Algfeley SG, Al-Rejaie SS, Nagi MN.

Drug Dev Res. 2019 Jun;80(4):475-480. doi: 10.1002/ddr.21520. Epub 2019 Jan 30.

PMID:
30701566
7.

Case Report: Hemophagocytic Lymphohistiocytosis Caused by Disseminated Histoplasmosis in a Venezuelan Patient with HIV and Epstein-Barr Virus Reactivation Who Traveled to Japan.

Tsuboi M, Nishijima T, Nagi M, Miyazaki Y, Teruya K, Kikuchi Y, Gatanaga H, Oka S.

Am J Trop Med Hyg. 2019 Feb;100(2):365-367. doi: 10.4269/ajtmh.18-0478.

PMID:
30652668
8.

FK506 Resistance of Saccharomyces cerevisiae Pdr5 and Candida albicans Cdr1 Involves Mutations in the Transmembrane Domains and Extracellular Loops.

Tanabe K, Bonus M, Tomiyama S, Miyoshi K, Nagi M, Niimi K, Chindamporn A, Gohlke H, Schmitt L, Cannon RD, Niimi M, Lamping E.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01146-18. doi: 10.1128/AAC.01146-18. Print 2019 Jan.

9.

CRISPR/Cas9 Genome Editing To Demonstrate the Contribution of Cyp51A Gly138Ser to Azole Resistance in Aspergillus fumigatus.

Umeyama T, Hayashi Y, Shimosaka H, Inukai T, Yamagoe S, Takatsuka S, Hoshino Y, Nagi M, Nakamura S, Kamei K, Ogawa K, Miyazaki Y.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00894-18. doi: 10.1128/AAC.00894-18. Print 2018 Sep.

10.

Micafungin Breakthrough Fungemia in Patients with Hematological Disorders.

Kimura M, Araoka H, Yamamoto H, Nakamura S, Nagi M, Yamagoe S, Miyazaki Y, Ogura S, Mitsuki T, Yuasa M, Kaji D, Kageyama K, Nishida A, Taya Y, Shimazu H, Ishiwata K, Takagi S, Yamamoto G, Asano-Mori Y, Uchida N, Wake A, Taniguchi S, Yoneyama A.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02183-17. doi: 10.1128/AAC.02183-17. Print 2018 May.

11.

Alleviation of lipopolysaccharide/d-galactosamine-induced liver injury in leukocyte cell-derived chemotaxin 2 deficient mice.

Okumura A, Saito T, Tobiume M, Hashimoto Y, Sato Y, Umeyama T, Nagi M, Tanabe K, Unoki-Kubota H, Kaburagi Y, Hasegawa H, Miyazaki Y, Yamagoe S.

Biochem Biophys Rep. 2017 Oct 13;12:166-171. doi: 10.1016/j.bbrep.2017.09.011. eCollection 2017 Dec.

12.

Intraspecies variation in the efficacy of adjunctive recombinant interferon-γ therapy against cryptococcal meningoencephalitis in mice.

Ikeda-Dantsuji Y, Nakamura S, Ohno H, Inukai T, Nagi M, Ueno K, Umeyama T, Kinjo Y, Yamagoe S, Shibuya K, Miyazaki Y.

Med Mycol. 2018 Apr 1;56(3):382-386. doi: 10.1093/mmy/myx063.

PMID:
28992282
13.

Bioenergy application of Dunaliella salina SA 134 grown at various salinity levels for lipid production.

Ahmed RA, He M, Aftab RA, Zheng S, Nagi M, Bakri R, Wang C.

Sci Rep. 2017 Aug 14;7(1):8118. doi: 10.1038/s41598-017-07540-x.

14.

Monitoring of Iron Depletion-Induced Mitophagy in Pathogenic Yeast.

Tanabe K, Nagi M.

Methods Mol Biol. 2018;1759:161-172. doi: 10.1007/7651_2017_40.

PMID:
28488243
15.

Scald management protocols - outcome differences in two different time periods using different treatment strategies.

Elmasry M, Steinvall I, Thorfinn J, Abbas AH, Adly OA, Abdelrahman I, Nagi MA, Sjoberg F.

Ann Burns Fire Disasters. 2016 Jun 30;29(2):139-143.

16.

Therapeutic potential of carfilzomib, an irreversible proteasome inhibitor, against acetaminophen-induced hepatotoxicity in mice.

Alanazi A, Algfeley SG, Al-Hosaini KA, Korashy HM, Imam F, Nagi MN.

J Biochem Mol Toxicol. 2017 Apr;31(4). doi: 10.1002/jbt.21877. Epub 2016 Nov 30.

PMID:
27900802
17.

Synthesis, biological evaluation and molecular modeling study of some new methoxylated 2-benzylthio-quinazoline-4(3H)-ones as nonclassical antifolates.

El-Messery SM, Hassan GS, Nagi MN, Habib EE, Al-Rashood ST, El-Subbagh HI.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4815-4823. doi: 10.1016/j.bmcl.2016.08.022. Epub 2016 Aug 11.

PMID:
27554444
18.

Iron-depletion promotes mitophagy to maintain mitochondrial integrity in pathogenic yeast Candida glabrata.

Nagi M, Tanabe K, Nakayama H, Ueno K, Yamagoe S, Umeyama T, Ohno H, Miyazaki Y.

Autophagy. 2016 Aug 2;12(8):1259-71. doi: 10.1080/15548627.2016.1183080. Epub 2016 Jun 27.

19.

Rutin Attenuates Carfilzomib-Induced Cardiotoxicity Through Inhibition of NF-κB, Hypertrophic Gene Expression and Oxidative Stress.

Imam F, Al-Harbi NO, Al-Harbia MM, Korashy HM, Ansari MA, Sayed-Ahmed MM, Nagi MN, Iqbal M, Khalid Anwer M, Kazmi I, Afzal M, Bahashwan S.

Cardiovasc Toxicol. 2017 Jan;17(1):58-66. doi: 10.1007/s12012-015-9356-5.

PMID:
26707720
20.

Interferon-γ promotes phagocytosis of Cryptococcus neoformans but not Cryptococcus gattii by murine macrophages.

Ikeda-Dantsuji Y, Ohno H, Tanabe K, Umeyama T, Ueno K, Nagi M, Yamagoe S, Kinjo Y, Miyazaki Y.

J Infect Chemother. 2015 Dec;21(12):831-6. doi: 10.1016/j.jiac.2015.08.001. Epub 2015 Oct 23.

PMID:
26477011
21.

Riboflavin attenuates lipopolysaccharide-induced lung injury in rats.

Al-Harbi NO, Imam F, Nadeem A, Al-Harbi MM, Korashy HM, Sayed-Ahmed MM, Hafez MM, Al-Shabanah OA, Nagi MN, Bahashwan S.

Toxicol Mech Methods. 2015;25(5):417-23. doi: 10.3109/15376516.2015.1045662. Epub 2015 Sep 11.

PMID:
26360969
22.

Prophylactic and Therapeutic Potential of Acetyl-L-carnitine against Acetaminophen-Induced Hepatotoxicity in Mice.

Alotaibi SA, Alanazi A, Bakheet SA, Alharbi NO, Nagi MN.

J Biochem Mol Toxicol. 2016 Jan;30(1):5-11. doi: 10.1002/jbt.21733. Epub 2015 Aug 12.

PMID:
26265018
23.

The mannoprotein TIR3 (CAGL0C03872g) is required for sterol uptake in Candida glabrata.

Inukai T, Nagi M, Morita A, Tanabe K, Aoyama T, Miyazaki Y, Bard M, Nakayama H.

Biochim Biophys Acta. 2015 Feb;1851(2):141-51. doi: 10.1016/j.bbalip.2014.11.002. Epub 2014 Nov 11.

PMID:
25463012
24.

Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors.

Al-Rashood ST, Hassan GS, El-Messery SM, Nagi MN, Habib EE, Al-Omary FAM, El-Subbagh HI.

Bioorg Med Chem Lett. 2014 Sep 15;24(18):4557-4567. doi: 10.1016/j.bmcl.2014.07.070. Epub 2014 Aug 4.

PMID:
25139568
25.

A possible antineoplastic potential of selective, irreversible proteasome inhibitor, carfilzomib on chemically induced hepatocarcinogenesis in rats.

Mansour MA, Aljoufi MA, Al-Hosaini K, Al-Rikabi AC, Nagi MN.

J Biochem Mol Toxicol. 2014 Sep;28(9):400-6. doi: 10.1002/jbt.21577. Epub 2014 May 27.

PMID:
24861196
26.

Genome-wide survey of transcriptional initiation in the pathogenic fungus, Candida glabrata.

Aoyama T, Nakayama H, Ueno K, Inukai T, Tanabe K, Nagi M, Bard M, Chibana H.

Genes Cells. 2014 Jun;19(6):478-503. doi: 10.1111/gtc.12147. Epub 2014 Apr 14.

27.

Possible role of selective, irreversible, proteasome inhibitor (carfilzomib) in the treatment of rat hepatocellular carcinoma.

Mansour MA, Aljoufi MA, Al-Hosaini K, Al-Rikabi AC, Nagi MN.

Chem Biol Interact. 2014 May 25;215:17-24. doi: 10.1016/j.cbi.2014.03.001. Epub 2014 Mar 13.

PMID:
24632418
28.

The heme-binding protein Dap1 links iron homeostasis to azole resistance via the P450 protein Erg11 in Candida glabrata.

Hosogaya N, Miyazaki T, Nagi M, Tanabe K, Minematsu A, Nagayoshi Y, Yamauchi S, Nakamura S, Imamura Y, Izumikawa K, Kakeya H, Yanagihara K, Miyazaki Y, Kugiyama K, Kohno S.

FEMS Yeast Res. 2013 Jun;13(4):411-21. doi: 10.1111/1567-1364.12043. Epub 2013 Apr 8.

29.

Nonclassical antifolates, part 3: synthesis, biological evaluation and molecular modeling study of some new 2-heteroarylthio-quinazolin-4-ones.

Al-Omary FA, Hassan GS, El-Messery SM, Nagi MN, Habib el-SE, El-Subbagh HI.

Eur J Med Chem. 2013 May;63:33-45. doi: 10.1016/j.ejmech.2012.12.061. Epub 2013 Feb 13.

PMID:
23454532
30.

The Candida glabrata sterol scavenging mechanism, mediated by the ATP-binding cassette transporter Aus1p, is regulated by iron limitation.

Nagi M, Tanabe K, Ueno K, Nakayama H, Aoyama T, Chibana H, Yamagoe S, Umeyama T, Oura T, Ohno H, Kajiwara S, Miyazaki Y.

Mol Microbiol. 2013 Apr;88(2):371-81. doi: 10.1111/mmi.12189. Epub 2013 Mar 11.

31.

Serum cholesterol promotes the growth of Candida glabrata in the presence of fluconazole.

Nagi M, Tanabe K, Nakayama H, Yamagoe S, Umeyama T, Oura T, Ohno H, Kajiwara S, Miyazaki Y.

J Infect Chemother. 2013 Feb;19(1):138-43. doi: 10.1007/s10156-012-0531-3. Epub 2012 Dec 12.

PMID:
23233084
32.

Chimeras of Candida albicans Cdr1p and Cdr2p reveal features of pleiotropic drug resistance transporter structure and function.

Tanabe K, Lamping E, Nagi M, Okawada A, Holmes AR, Miyazaki Y, Cannon RD, Monk BC, Niimi M.

Mol Microbiol. 2011 Oct;82(2):416-33. doi: 10.1111/j.1365-2958.2011.07820.x. Epub 2011 Sep 19.

33.

Growth defects resulting from inhibiting ERG20 and RAM2 in Candida glabrata.

Nakayama H, Ueno K, Uno J, Nagi M, Tanabe K, Aoyama T, Chibana H, Bard M.

FEMS Microbiol Lett. 2011 Apr;317(1):27-33. doi: 10.1111/j.1574-6968.2010.02205.x. Epub 2011 Jan 31.

34.

Transcription factors CgUPC2A and CgUPC2B regulate ergosterol biosynthetic genes in Candida glabrata.

Nagi M, Nakayama H, Tanabe K, Bard M, Aoyama T, Okano M, Higashi S, Ueno K, Chibana H, Niimi M, Yamagoe S, Umeyama T, Kajiwara S, Ohno H, Miyazaki Y.

Genes Cells. 2011 Jan;16(1):80-9. doi: 10.1111/j.1365-2443.2010.01470.x.

35.

Thymoquinone attenuates diethylnitrosamine induction of hepatic carcinogenesis through antioxidant signaling.

Sayed-Ahmed MM, Aleisa AM, Al-Rejaie SS, Al-Yahya AA, Al-Shabanah OA, Hafez MM, Nagi MN.

Oxid Med Cell Longev. 2010 Jul-Aug;3(4):254-61. doi: 10.4161/oxim.3.4.12714.

36.

Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats.

Nagi MN, Al-Shabanah OA, Hafez MM, Sayed-Ahmed MM.

J Biochem Mol Toxicol. 2011 May-Jun;25(3):135-42. doi: 10.1002/jbt.20369. Epub 2010 Oct 18.

PMID:
20957680
37.

Thymoquinone supplementation reverses acetaminophen-induced oxidative stress, nitric oxide production and energy decline in mice liver.

Nagi MN, Almakki HA, Sayed-Ahmed MM, Al-Bekairi AM.

Food Chem Toxicol. 2010 Aug-Sep;48(8-9):2361-5. doi: 10.1016/j.fct.2010.05.072. Epub 2010 Jun 1.

PMID:
20561950
38.

Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.

Al-Omary FA, Abou-Zeid LA, Nagi MN, Habib el-SE, Abdel-Aziz AA, El-Azab AS, Abdel-Hamide SG, Al-Omar MA, Al-Obaid AM, El-Subbagh HI.

Bioorg Med Chem. 2010 Apr 15;18(8):2849-63. doi: 10.1016/j.bmc.2010.03.019. Epub 2010 Mar 12.

PMID:
20350811
39.

Serum or bile affects the in vitro azole susceptibilities of Candida spp.

Nagi M, Tanabe K, Takano Y, Kikuchi K, Miyazaki Y, Niimi M.

Jpn J Infect Dis. 2009 Jul;62(4):306-8.

41.

Comparison of two imaging protocols for acute stroke: unenhanced cranial CT versus a multimodality cranial CT protocol with perfusion imaging.

Langer RD, Neidl van Gorkom K, Al Kaabi HO, Torab F, Czechowski J, Nagi M, Ashish GM.

Australas Radiol. 2007 Dec;51(6):532-7.

PMID:
17958687
42.

Thymoquinone supplementation prevents the development of gentamicin-induced acute renal toxicity in rats.

Sayed-Ahmed MM, Nagi MN.

Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):399-405.

PMID:
17439407
43.
44.

Surgical management of inferior turbinate hypertrophy in nonallergic rhinitis.

Nagi MM, Desrosiers M.

Clin Allergy Immunol. 2007;19:375-81. Review. No abstract available.

PMID:
17153027
45.

Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.

Al-Rashood ST, Aboldahab IA, Nagi MN, Abouzeid LA, Abdel-Aziz AA, Abdel-Hamide SG, Youssef KM, Al-Obaid AM, El-Subbagh HI.

Bioorg Med Chem. 2006 Dec 15;14(24):8608-21. Epub 2006 Sep 12.

PMID:
16971132
46.

Neuroprotective effects of thymoquinone against transient forebrain ischemia in the rat hippocampus.

Al-Majed AA, Al-Omar FA, Nagi MN.

Eur J Pharmacol. 2006 Aug 14;543(1-3):40-7. Epub 2006 Jun 3.

PMID:
16828080
47.

Immediate and delayed treatments with curcumin prevents forebrain ischemia-induced neuronal damage and oxidative insult in the rat hippocampus.

Al-Omar FA, Nagi MN, Abdulgadir MM, Al Joni KS, Al-Majed AA.

Neurochem Res. 2006 May;31(5):611-8. Epub 2006 May 23.

PMID:
16770732
48.

Evaluation of a programme for control of schistosoma haematobium infection in Yemen.

Nagi MA.

East Mediterr Health J. 2005 Sep-Nov;11(5-6):977-87.

50.

Algorithms for management of chronic rhinosinusitis.

Nagi MM, Desrosiers MY.

Otolaryngol Clin North Am. 2005 Dec;38(6):1137-41, vii.

PMID:
16326173

Supplemental Content

Support Center